Editorial Comment: Risk Factors for Penile Fracture After Intraliesional Collagenase Clostridium histolyticum in Peyronie’s Disease

Isaac Zucker 1, Sirpi Nackeeran 2, Sahaam Mirza 3, Thomas A Masterson 4

1 Department of Urology, University of Toledo, Toledo, OH; 2 Department of Urology, University of California San Diego, San Diego, CA; 3 Kansas City University, Kansas City, MO; 4 Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, FL

Urology. 2024 Jan:183:117-120.
DOI: 10.1016/j.urology.2023.10.019 | ACCESS: 37949243

Luciano A. Favorito 1, 2
1 Unidade de Pesquisa Urogenital - Universidade do Estado do Rio de Janeiro - Uerj, Rio de Janeiro, RJ, Brasil; 2 Serviço de Urologia, Hospital Federal da Lagoa, Rio de Janeiro, RJ, Brasil

COMMENT

The treatment of Peyronie’s disease (PD) is challenging. The paper of Zucker et al. (1) shows an important complication after the use of Intraliesional Collagenase Clostridium histolyticum (CCh) in PD: Penile fracture. Sexual intercourse represented the main cause of PF in USA, Europe and Brazil because intercourse is generally associated with high-energy traumas (2). Recent papers showed that, the positions with the “man on top” and “doggy style” were considered the most severe, presenting greater association with urethral and bilateral lesions of the corpora cavernosa (2, 3).

In the present paper the authors studied retrospectively 1541 patients that received at least one injection of CCh for PD. Of them, 0.7% (11/1541) suffered corporal rupture occurred at a median of 8 days after CCh injection. The majority of fractures were secondary to spontaneous erections or sexual intercourse. Finally, six patients had their fracture repaired surgically while the remaining were managed conservatively. The authors concluded that intraliesional CCh can lead to corporal rupture and the most fractures occurred within 2 weeks of CCh injections and were associated with sexual intercourse and spontaneous morning erections.

CONFLICT OF INTEREST

None declared.
REFERENCES


ARTICLE INFO

Luciano A. Favorito
https://orcid.org/0000-0003-1562-6068

Int Braz J Urol. 2024; 50: 223-4

Submitted for publication: January 05, 2024
Accepted: January 25, 2024
Published as Ahead of Print: January 31, 2024

Correspondence address:
Luciano Alves Favorito, MD, PhD
Rua Professor Gabizo, 104/201 – Tijuca
Rio de Janeiro, RJ, 20271-320, Brazil
Fax: +55 21 38728-802
E-mail: lufavorito@yahoo.com.br